Advertisement
Screener

LARIMAR THERAPEUTICS, INC. (LRMR) Graph

LRMR Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $28.00M; Operating expenses $34.35M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $25.03M; Operating expenses $31.12M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development $59.37M*; Operating expenses $64.02M*; Income tax $0.00*.
  • 2025-09-30: Revenue (m); Research and development $44.93M; Operating expenses $49.50M; Income tax $0.00.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$28.00M$34.35M(m)-$32.78M
2026-03-31(m)$25.03M$31.12M(m)-$29.61M
2025-12-31(m)$59.37M*$64.02M*$0.00*-$62.50M*
2025-09-30(m)$44.93M$49.50M$0.00-$47.71M
2025-06-30(m)$23.37M$27.79M$0.00-$26.18M
2025-03-31(m)$26.55M$31.19M(m)-$29.28M
2024-09-30(m)$13.92M$18.26M$0.00-$15.50M
2024-06-30(m)$19.68M$24.60M$0.00-$21.63M
2024-03-31(m)$12.94M$16.73M(m)-$14.65M
2023-09-30(m)$6.58M$10.34M(m)-$9.06M
2023-06-30(m)$5.88M$9.62M(m)-$8.37M
2023-03-31(m)$4.56M$7.64M(m)-$6.53M
2022-09-30(m)$5.58M$8.51M(m)-$8.32M
2022-06-30(m)$5.64M$8.69M(m)-$8.67M
2022-03-31(m)$5.81M$8.89M(m)-$8.94M
2021-09-30(m)$14.03M$16.73M(m)-$16.80M
2021-06-30(m)$9.10M$12.54M(m)-$12.61M
2021-03-31(m)$8.97M$12.11M(m)-$12.09M
2020-09-30(m)$6.92M$10.34M(m)-$10.27M
2020-06-30(m)$8.91M$11.40M(m)-$11.33M
2020-03-31$0.00$5.01M$6.67M(m)-$6.67M
2019-12-31$0.00(m)$7.28M(m)-$7.25M
2019-09-30$0.00$8.03M$8.63M(m)-$8.63M
2019-06-30$0.00$3.13M$3.70M(m)-$3.70M
2019-03-31$0.00$9.63M$13.28M(m)-$4.72M
2018-12-31$0.00(m)$14.69M(m)-$14.57M
2018-09-30$0.00$11.83M$15.17M(m)-$15.07M
2018-06-30$0.00$12.21M$15.56M(m)-$15.78M
2018-03-31$0.00$12.43M$15.70M(m)-$15.96M
2017-12-31$0.00(m)$13.36M(m)(m)
2017-09-30$0.00$9.72M$12.84M(m)-$12.59M
2017-06-30$0.00$10.53M$13.54M(m)-$13.35M
2017-03-31$0.00$9.68M$13.27M(m)-$13.01M
2016-12-31$0.00(m)$10.47M(m)(m)
2016-09-30$0.00$10.00M$14.83M(m)-$14.68M
2016-06-30$0.00$10.16M$15.06M(m)-$15.03M
2016-03-31$0.00$12.50M$17.86M(m)-$17.74M
2015-12-31$0.00(m)$23.25M(m)(m)
2015-09-30$0.00$14.17M$19.72M(m)-$19.88M
2015-06-30$0.00$12.53M$17.61M(m)-$17.76M
2015-03-31$0.00$10.21M$13.24M(m)-$13.47M
2014-12-31$0.00(m)$10.66M(m)(m)
2014-09-30$0.00$12.08M$14.36M(m)-$14.69M
2014-06-30$0.00$4.70M$5.99M(m)-$6.40M
2014-03-31$0.00$3.27M$4.52M(m)-$4.46M
2013-12-31$0.00(m)$3.76M(m)(m)
2013-09-30$0.00$2.44M$3.52M(m)-$3.50M
2013-06-30$0.00$1.96M$2.98M(m)-$3.14M
2013-03-31$0.00(m)$3.52M(m)(m)

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$53.03M$65.47M(m)-$62.40M
2025-06-30(m)$49.92M$58.98M$0.00-$55.46M
2024-06-30(m)$32.62M$41.33M$0.00-$36.28M
2023-06-30(m)$10.44M$17.26M(m)-$14.89M
2022-06-30(m)$11.45M$17.57M(m)-$17.61M
2021-06-30(m)$18.08M$24.65M(m)-$24.70M
2020-06-30(m)$13.91M$18.07M(m)-$18.00M
2019-06-30$0.00$7.35M$8.43M(m)-$8.43M
2018-06-30$0.00$24.64M$31.26M(m)-$31.73M
2017-06-30$0.00$20.20M$26.80M(m)-$26.36M
2016-06-30$0.00$22.66M$32.92M(m)-$32.76M
2015-06-30$0.00$22.74M$30.85M(m)-$31.23M
2014-06-30$0.00$7.97M$10.51M(m)-$10.86M
2013-06-30(m)$4.59M$6.50M(m)-$6.68M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$94.85M$108.48M$0.00-$103.17M
2024-09-30(m)$46.54M$59.60M$0.00-$51.78M
2023-09-30(m)$17.02M$27.60M(m)-$23.96M
2022-09-30(m)$17.03M$26.09M(m)-$25.93M
2021-09-30(m)$32.10M$41.38M(m)-$41.50M
2020-09-30(m)$20.83M$28.41M(m)-$28.28M
2019-09-30$0.00$15.38M$17.06M(m)-$17.06M
2018-09-30$0.00$36.47M$46.43M(m)-$46.80M
2017-09-30$0.00$29.93M$39.64M(m)-$38.94M
2016-09-30$0.00$32.66M$47.75M(m)-$47.44M
2015-09-30$0.00$36.91M$50.57M(m)-$51.11M
2014-09-30$0.00$20.05M$24.87M(m)-$25.55M
2013-09-30(m)$7.04M$10.02M(m)-$10.18M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$154.22M$172.50M$0.00-$165.67M
2024-12-31(m)$73.28M$90.89M$0.00-$80.60M
2023-12-31(m)$27.67M$41.76M$0.00-$36.95M
2022-12-31(m)$24.25M$36.53M$0.00-$35.35M
2021-12-31(m)$38.40M$50.47M$0.00-$50.64M
2020-12-31(m)$31.41M$42.80M$0.00-$42.48M
2019-12-31$0.00$20.79M$23.21M$0.00-$23.13M
2018-12-31$0.00$47.93M$61.12M$0.00-$61.37M
2017-12-31$0.00$40.84M$53.00M$0.00-$52.03M
2016-12-31$0.00$39.94M$58.23M$0.00-$57.88M
2015-12-31$0.00$54.62M$73.81M$0.00-$74.29M
2014-12-31$0.00$27.39M$35.53M$0.00-$36.48M
2013-12-31$0.00$9.56M$13.78M$0.00-$14.03M
2012-12-31$0.00$11.54M$13.79M$0.00-$13.88M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
Vogenx, Inc. (VOGX)United States$0.355B
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58